San Diego, United States
Plexium, founded in 2018, is a pioneering biotechnology company based in the United States. The company is redefining the landscape of targeted protein degradation (TPD) with the ambitious mission of "Pushing the Boundaries of Targeted Protein Degradation to Improve Lives."
Plexium's innovation primarily revolves around its DELTA Discovery™ platform, which includes a unique ultra-high throughput (uHTS) cell-based screening capability. This technology positions Plexium as a leader with the potential to deliver first-in-class and best-in-class treatments, addressing high unmet medical needs in the biotechnology, health care, health and wellness, and pharmaceutical sectors.
Having secured a substantial $102.00M Series B investment on 23 February 2022, Plexium is backed by an impressive roster of investors, including Lux Capital, Neotribe Ventures, RA Capital Management, Pivotal bioVenture Partners, and SoftBank Vision Fund, underscoring strong confidence in its innovative approach and market potential.
